{"type":"rich","version":"1.0","provider_name":"Transistor","provider_url":"https://transistor.fm","author_name":"The Emerging Biotech Leader","title":"Changing the Patient Care Paradigm - Leah Damesek : 20","html":"","width":"100%","height":180,"duration":1372,"description":"“There are clear distinctions, as we've talked about, between device and pharma from a medical affairs perspective. I think they each require this special touch and strategic medical affairs plan, but I think what we're also converging on is that they’re almost more similar than we think.’” Leah Damesek, Vice President of Medical Affairs, SSI Strategy. Disruption. It’s a word that many associate with dramatic or abrupt change. But in order to disrupt something in biotech, particularly shifting a standard of care from one type of treatment to a new protocol using a medical device, there has to be collective, cohesive, methodical buy-in. In Episode 19 of the Emerging Biotech Leader, our interview with Shon Chakrabarti of Inari Medical echoed how disrupting a care pathway has many moving parts. Now, in Episode 20, Kim Kushner, Ramin Farhood, and a new voice from the SSI team, Leah Damesek, Vice President of Medical Affairs Strategy, continue exploring what it takes to bring disruptive devices to market. Listen in to observe a few overarching themes that emerge and guide the conversation.Leah and Ramin share their thoughts and experience on changing a care paradigm to meet an unmet needAll three discuss the actions required when disrupting a care pathway change the physician baseAnd lastly, Kim, Ramin, and Leah circle back on the use of real-world evidence in changing physician behaviorThe trio keep no secrets–the medical device industry is more advanced, compared to pharma, when it comes to strategically utilizing real-world evidence. And as you’ll hear, this is brought up not to poke holes but to provoke thought and understanding for anyone looking to shift from one sector or the other. Throughout this episode, Kim, Ramin, and Leah also discern additional differences and similarities between device and pharma. What’s vital to both–no matter which side of the industry you find yourself on–is that the main goal never deviates from this credo: do right by the...","thumbnail_url":"https://img.transistorcdn.com/ifry0mqC60CO4NUZn9GSCTvcoZ9yKEWu4twnqKmJQQ0/rs:fill:0:0:1/w:400/h:400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS80NzEy/MTZiMmZlODIyZDI4/OTliMGJiOWQ0ZDUx/MDhmNi5wbmc.webp","thumbnail_width":300,"thumbnail_height":300}